Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.

@article{Goto2012EpidermalGF,
  title={Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.},
  author={Koichi Goto and Yukito Ichinose and Yuichiro Ohe and Nobuyuki Yamamoto and Shunichi Negoro and Kazuto Nishio and Yohji Itoh and Haiyi Jiang and Emma L Duffield and Rose McCormack and Nagahiro George Saijo and Tony C. W. Mok and Masahiro Fukuoka},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2012},
  volume={7 1},
  pages={115-21}
}
INTRODUCTION In IPASS (IRESSA Pan-Asia Study), clinically selected patients with pulmonary adenocarcinoma received first-line gefitinib or carboplatin/paclitaxel. This preplanned, exploratory analysis was conducted to increase understanding of the use of surrogate samples, such as serum, versus tumor biopsy samples for determining EGFR mutation status in the Japanese cohort (n = 233). METHODS EGFR mutations were assessed using tumor tissue-derived DNA (n = 91) and circulating free (cf) DNA… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 84 extracted citations

Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2017
View 1 Excerpt
Highly Influenced

Molecular pathology in real time

Cancer and Metastasis Reviews • 2016
View 11 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Similar Papers

Loading similar papers…